文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

缓刑人员在获取和使用阿片类物质使用障碍药物方面的障碍。

Probation clients' barriers to access and use of opioid use disorder medications.

作者信息

Reichert Jessica, Gleicher Lily

机构信息

Illinois Criminal Justice Information Authority, Center for Justice Research and Evaluation, 300 W. Adams St., Suite 200, Chicago, IL, 60606, USA.

出版信息

Health Justice. 2019 May 28;7(1):10. doi: 10.1186/s40352-019-0089-6.


DOI:10.1186/s40352-019-0089-6
PMID:31139961
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6717960/
Abstract

BACKGROUND: There is a gap between evidence-based treatment with medications for opioid use disorders (OUDs) and current practices of probation departments who supervise individuals with OUDs. Many probationers with OUDs cannot access FDA-approved medications to treat their disorders despite the strong evidence of their effectiveness. The barriers to medications for those under probation supervision include practitioners' negative attitudes toward medications, costs, stigma, and diversion risk. Probation officers have an ethical obligation to help their clients reduce barriers to access the care they need which in turn can improve their outcomes and increase public safety. RESULTS: The current study explores how probation departments respond to probationers with OUDs, focusing on the barriers to accessing OUD medications based on a survey of probation department directors/administrators (hereafter referred to as probation department leaders) in Illinois (N = 26). A majority of probation department leaders reported perceived staff barriers to their clients accessing medications. Reasons included lack of medical personnel experience, cost, need for guidance on medications, and regulations set by their organization or jurisdiction that prohibit client use of medications. Probation department leaders reported knowing less about the use of methadone and how it is administered, compared to buprenorphine and naltrexone. In addition, probation department leaders were generally more open to referring clients for treatment that include buprenorphine or naltrexone compared to methadone. Despite slightly less training or familiarity with methadone than the other medications, the number of probation department leaders who knew where to refer someone for each of the three FDA-approved medications was similar. CONCLUSIONS: The current study found probation department leaders perceive some barriers to their staff linking or referring their clients to OUD medications. Study findings indicate a need for administration- and staff-level training, interagency collaboration, and policy changes to increase access to, education on, and use of, medications for probation clients. Such efforts will ultimately help probation clients with OUDs stabilize and adhere to other probation requirements and engage in behavioral therapy, which may result in positive outcomes such as reduced recidivism, increased quality of life, and reduced mortality.

摘要

背景:阿片类物质使用障碍(OUD)的循证药物治疗与监督患有OUD的个体的缓刑部门当前的做法之间存在差距。尽管有充分证据证明其有效性,但许多患有OUD的缓刑人员无法获得美国食品药品监督管理局(FDA)批准的药物来治疗他们的疾病。缓刑监督下的人员获取药物的障碍包括从业者对药物的消极态度、成本、污名以及药物转移风险。缓刑官有道德义务帮助他们的客户减少获取所需护理的障碍,这反过来可以改善他们的结果并提高公共安全。 结果:本研究探讨了缓刑部门如何应对患有OUD的缓刑人员,重点关注基于对伊利诺伊州缓刑部门主管/管理人员(以下简称缓刑部门负责人)的调查(N = 26)获取OUD药物的障碍。大多数缓刑部门负责人报告称,他们认为工作人员在客户获取药物方面存在障碍。原因包括缺乏医务人员经验、成本、药物使用指导需求以及其组织或管辖区域制定的禁止客户使用药物的规定。与丁丙诺啡和纳曲酮相比,缓刑部门负责人报告称对美沙酮的使用及其给药方式了解较少。此外,与美沙酮相比,缓刑部门负责人通常更愿意将客户转介接受包括丁丙诺啡或纳曲酮的治疗。尽管与其他药物相比,对美沙酮的培训或熟悉程度略低,但知道将某人转介至三种FDA批准药物中每种药物治疗地点的缓刑部门负责人数量相似。 结论:本研究发现缓刑部门负责人认为其工作人员在将客户与OUD药物联系起来或转介客户使用OUD药物方面存在一些障碍。研究结果表明需要进行行政和工作人员层面的培训、跨机构合作以及政策变革,以增加缓刑客户获取、接受药物教育以及使用药物的机会。这些努力最终将帮助患有OUD的缓刑客户稳定下来并遵守其他缓刑要求,参与行为治疗,这可能会带来诸如降低再犯率、提高生活质量和降低死亡率等积极结果。

相似文献

[1]
Probation clients' barriers to access and use of opioid use disorder medications.

Health Justice. 2019-5-28

[2]
Court personnel attitudes towards medication-assisted treatment: A state-wide survey.

J Subst Abuse Treat. 2019-6-28

[3]
Barriers and facilitators to the use of medication for opioid use disorder within the criminal justice system: Perspectives from clinicians.

J Subst Use Addict Treat. 2023-6

[4]
Understanding and co-managing medication treatment options for opioid use disorder.

Intern Emerg Med. 2022-10

[5]
Cost-effectiveness of Treatments for Opioid Use Disorder.

JAMA Psychiatry. 2021-7-1

[6]
Patients' Beliefs About Medications are Associated with Stated Preference for Methadone, Buprenorphine, Naltrexone, or no Medication-Assisted Therapy Following Inpatient Opioid Detoxification.

J Subst Abuse Treat. 2016-7

[7]
Evaluation of medications used for opioid use disorder in emergency departments: A cross-sectional analysis of the 2020 National Hospital Ambulatory Medical Care Survey.

Am J Emerg Med. 2024-8

[8]
Structural and organizational factors shaping access to medication treatment for opioid use disorder in community supervision.

Drug Alcohol Depend. 2021-9-1

[9]
Beliefs about medications for opioid use disorder among Florida criminal problem-solving court & dependency court staff.

Am J Drug Alcohol Abuse. 2020-11-1

[10]
Perceptions of buprenorphine barriers and efficacy among nurse practitioners and physician assistants.

Addict Sci Clin Pract. 2022-8-9

引用本文的文献

[1]
A mixed-method exploratory assessment of provider-based stigma of opioid use disorder (OUD) and support for medications for opioid use disorder (MOUD) in carceral settings.

Harm Reduct J. 2025-8-18

[2]
Improving first responders' perceptions of overdose events and survivors through tailored occupational health-focused training co-facilitated by overdose survivors.

Health Justice. 2024-12-19

[3]
Linkage facilitation for opioid use disorder in criminal legal system contexts: a primer for researchers, clinicians, and legal practitioners.

Health Justice. 2024-8-29

[4]
Cascade of care for substance use and mental health disorders for justice-involved populations.

J Subst Use Addict Treat. 2024-12

[5]
Opioid Misuse and Associated Health Risks among Adults on Probation and Parole: Prevalence and Correlates 2015-2020.

Subst Use Misuse. 2024

[6]
Strengthening Addiction Care Continuum Through Community Consortium in Vietnam: Protocol for a Cluster-Randomized Controlled Trial.

JMIR Res Protoc. 2023-3-22

[7]
Improving Access to Evidence-Based Medical Treatment for Opioid Use Disorder: Strategies to Address Key Barriers within the Treatment System.

NAM Perspect. 2020-4-27

[8]
Prevalence and risk factors for opioid related mortality among probation clients in an American city.

J Subst Abuse Treat. 2022-6

[9]
A national survey of barriers and facilitators to medications for opioid use disorder among legal-involved veterans in the Veterans Health Administration.

Subst Abus. 2022

[10]
Tailoring services in opioid treatment programs for patients involved in America's criminal justice system: national associations and variation by state and Medicaid expansion status.

Subst Abuse Treat Prev Policy. 2021-6-19

本文引用的文献

[1]
A New Year's Wish on Opioids.

JAMA. 2018-2-13

[2]
Only One In Twenty Justice-Referred Adults In Specialty Treatment For Opioid Use Receive Methadone Or Buprenorphine.

Health Aff (Millwood). 2017-12

[3]
Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.

J Subst Abuse Treat. 2017-7-3

[4]
Why aren't physicians prescribing more buprenorphine?

J Subst Abuse Treat. 2017-7

[5]
Trends and correlates of substance use disorders among probationers and parolees in the United States 2002-2014.

Drug Alcohol Depend. 2016-10-1

[6]
Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders.

N Engl J Med. 2016-3-31

[7]
Community correctional agents' views of medication-assisted treatment: Examining their influence on treatment referrals and community supervision practices.

Subst Abus. 2016

[8]
Methadone continuation versus forced withdrawal on incarceration in a combined US prison and jail: a randomised, open-label trial.

Lancet. 2015-7-25

[9]
Effect of an organizational linkage intervention on staff perceptions of medication-assisted treatment and referral intentions in community corrections.

J Subst Abuse Treat. 2015-3

[10]
The impact of prior authorization on buprenorphine dose, relapse rates, and cost for Massachusetts Medicaid beneficiaries with opioid dependence.

Health Serv Res. 2014-12

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索